Data sharing statement
The data of this study is available on request from the corresponding author.
Article information
Corresponding Author: Dr. Alberto J. Espay Gardner Family Center for Parkinson's Disease and Movement Disorders, Department of Neurology, University of Cincinnati, Cincinnati, Ohio, USA Tel: +1 (513)558-4035; e-mail: [email protected].
Author Contributions: All authors had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. D
Concept and design: Dwivedi, Espay
Acquisition, analysis, or interpretation of data: All authors
Drafting of the manuscript: Dwivedi
Critical revision of the manuscript for important intellectual content: All authors
Statistical analysis: Dwivedi.
Obtained funding: N/A
Administrative, technical, or material support: Abanto, Espay
Supervision: Espay
Conflict of Interest Disclosures
Drs. Dwivedi and Abanto have nothing to disclose.
Dr. Schneider has the following to disclose: NIH: P30 AG066530 (ADRC), R01 AG052510 (S-citalopram), R01 AG053267 (DIAN-TU), R01 AG054434 (APOE and DHA), R01 AG062687 (phenserine/exosomes), R01 AG051346 (NoMAD), R01 AG055444 (Banner API), P01 AG02350 (vascular), R01 AG063826 (allopregnanolone), R01 AG074983 (Aβ/tau vaccine), others; State of California CADC 15-10291; Alzheimer’s Association (allopregnanolone). Contracts or grants from Abbott, Eli Lilly, Roche/Genentech, Eisai, Biogen. Grants from Washington University, St. Louis/NIA DIAN-TU, UCSD ADCS, USC ATRI. Consulting: ImmunoBrain Checkpoint Ltd, BioVie, AC Immune, Athira, Avid/Lilly, BMS, Lighthouse (Cortexyme), Linus Health Merck, Muna Ltd, Neurim Ltd, NeuroDiagnostics Inc, Ono Ltd, Otsuka/Lundbeck, Roche/Genentech, Pharmatrophix (Stanford), Novo Nordisk, Vivli.org. The Lancet Commission on Dementia Prevention and Care. The Della Martin Foundation.
Dr. Schrag has received grant support from the NIH, compensation for chairing the DSMB of the REVISION trial, and consulting fees from Guidepoint, Raymond James, Greycourt, and Labaton Sucharow LLP and for expert testimony unrelated to the current material.
Dr. Herrup has nothing to disclose.
Dr. Widera has nothing to disclose.
Dr. Mahajan has received funding from the Parkinson’s Foundation, Sunflower Parkinson’s disease foundation and Dystonia Medical Research Foundation outside of the submitted work. He reports no conflicts of interest.
Dr. Howard received support from the National Institute for Health Research University College Hospital London Biomedical Research Centre.
Dr. Espay has received grant support from the NIH and the Michael J Fox Foundation; personal compensation as a consultant/scientific advisory board member for Mitsubishi Tanabe Pharma America (formerly, Neuroderm), Amneal, Acadia, Avion, Acorda, Bial, Kyowa Kirin, Supernus (formerly, USWorldMeds), NeuroDiagnostics, Inc (SYNAPS Dx), Intrance Medical Systems, Inc., Merz, Praxis Precision Medicines, Citrus Health, and Herantis Pharma; Data Safety Monitoring Board (chair) of AskBio; and publishing royalties from Lippincott Williams & Wilkins, Cambridge University Press, and Springer. He cofounded REGAIN Therapeutics and is co-inventor of the patent “Compositions and methods for treatment and/or prophylaxis of proteinopathies.” He serves on the editorial boards of the Journal of Parkinson’s Disease, Journal of Alzheimer’s Disease, European Journal of Neurology, Movement Disorders Clinical Practice, and JAMA Neurology.